Pfizer and BioNTech ask EU to clear vaccine for 12 to 15-year-olds
In a statement on Friday, the two companies said their submission to the European Medicines Agency (EMA) was based on an advanced study in more than 2,000 adolescents that showed the vaccine to be safe and effective.
The children will continue to be monitored for longer-term protection and safety for another two years.
The move could offer younger and less at-risk populations in Europe access to the jabs for the first time.
BioNTech and Pfizer had previously requested their emergency use authorisation with the US Food and Drug Administration to be extended to children aged 12-15. ■